GlassScriptPhysician profile
Martin D Mckee
NPI 1205920634
$741.19
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.52 · 2020: $238 · 2021: $273 · 2022: $145.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $195.64 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.58 | 2019-2022 | |
| Novo Nordisk INC | $72.60 | 2019-2022 | |
| Allergan, INC. | $67.00 | 2020 | |
| Glaxosmithkline, LLC. | $59.06 | 2019-2021 | |
| Genentech USA, INC. | $56.88 | 2020-2021 | |
| Eisai INC. | $26.90 | 2020-2021 | |
| Nalpropion Pharmaceuticals LLC | $25.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.80 | 2021 | |
| Abbott Laboratories | $20.41 | 2022 | |
| Lilly USA, LLC | $19.94 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.50 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.58 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.